lacutamab   Click here for help

GtoPdb Ligand ID: 14662

Synonyms: IPH-4102 | IPH4102
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lacutamab (IPH4102) is a humanized anti-KIR3DL2, cytotoxicity-inducing, monoclonal antibody [3-4,6].
Click here for help
References
1. Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS et al.. (2019)
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Lancet Oncol, 20 (8): 1160-1170. [PMID:31253572]
2. Bonnafous C, Sicard H, Buffet R. (2014)
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma.
Patent number: WO2014128221A1. Assignee: Innate Pharma. Priority date: 20/02/2013. Publication date: 28/08/2014.
3. Gauthier L, Schneider N. (2019)
Humanized antibodies with increased stability.
Patent number: US10280222B2. Assignee: Innate Pharma SA. Priority date: 12/03/2015. Publication date: 07/05/2019.
4. Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C et al.. (2014)
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
Cancer Res, 74 (21): 6060-70. [PMID:25361998]
5. Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. (2015)
A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
Oncoimmunology, 4 (9): e1022306. [PMID:26405593]
6. Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. (2018)
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
Expert Opin Investig Drugs, 27 (8): 691-697. [PMID:30001170]